Pure Global: Brazil's ANVISA Shakeup - Navigating MedTech's Hidden Compliance Traps.

Brazil's MedTech market is undergoing a seismic regulatory shift. ANVISA, the national health surveillance agency, is rolling out a series of major updates, including the new RDC 848/2024, which redefines essential safety and performance requirements with a strong focus on lifecycle risk management and cybersecurity. This is creating a new, complex web of compliance for manufacturers.

This episode of LATAM MedTech Insights unpacks the practical implications of these changes. We go beyond the headlines to explore the operational hurdles, such as the mandatory transition to a new digital certificate platform by 2025. We reveal the hidden pitfalls that are already causing submission delays and rejections for unprepared foreign companies trying to enter or stay in Latin America's largest market.

We explore the real-world scenario of a mid-sized European device maker whose Brazilian market entry was stalled for six months. They successfully passed clinical trials, but their entire submission was rejected due to a documentation technicality in ANVISA’s new, confusing certificate issuance system. This episode breaks down how to avoid that costly mistake.

Key Takeaways:
1. How does ANVISA's new RDC 848/2024 fundamentally change safety requirements for your device?
2. Is your current technical dossier prepared for the upcoming cybersecurity mandates?
3. What are the biggest pitfalls when transitioning from the old 'Sicert' to the new submission platform?
4. Why might your existing risk classification under RDC 751 need urgent re-evaluation?
5. How will these new rules impact your timeline and budget for entering the Brazilian market?
6. Are you treating Brazilian compliance as a lifecycle activity or a one-time submission?
7. What specific documentation changes are required for the new 2025 certificate tool?

Don't let regulatory hurdles block your access to the vibrant Brazilian market. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, combining deep local expertise with advanced AI tools to streamline global market access. We act as your local representative, manage technical dossiers, and ensure continuous compliance in over 30 markets. To build a resilient regulatory strategy for Brazil and beyond, contact us at info@pureglobal.com or visit https://pureglobal.com/.